Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-28. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Moreover, Esimone's research team was the first to demonstrate the occurrence of the FOX-1 gene, responsible for expressing the AmpC enzyme in gram-negative bacteria in Nigeria. This enzyme significantly enhances the ability of organisms to resist cephamycin antibiotics.
== Partnerships == On 5 September 2012, Nokia announced a deal with the chain to offer wireless charging facilities in its cafés. On May 28, 2013, Hilton Worldwide announced they had signed an exclusive agreement for Coffee Bean to provide in-room coffee and tea for all Hilton hotels in North America, South America, and Central America. Green Mountain Coffee Roasters announced on May 29, 2013, that they had partnered with Coffee Bean to create a K-Cup for Keurig single-cup brewing systems, available in the US as of 2014. On August 24, 2015, the firm announced they had signed an exclusive area development agreement with South Korean retail conglomerate E-LAND to enter into the Chinese market. On July 21, 2020, the Coffee Bean & Tea Leaf entered into a partnership with fast casual chain Smashburger, and began incorporating Coffee Bean & Tea Leaf products into their menu.
== Patents == Compositions and methods for inducing apoptosis. J. Kopeček, J. Yang, T.-W. Chu. (2019) US 10,251,906 B2. Compositions and methods for using albumin-based nanomedicines. J. Kopeček, J. Yang. US 10,925,973 (Feb. 23, 2021) Polymeric drug delivery conjugates and methods of making and using thereof. H. Pan, J. Yang, P. Kopečková, K. Luo, J. Kopeček (2016) US 9,289,510 B2 Hydrogels of water-soluble polymers crosslinked by protein domains. J. Kopeček, R. Stewart, K. Caldwell, C. Wang, C-H. Ho (2007) US 7,179,487 Synthetic polymeric drugs. J. Kopeček, P. Rejmanová, J. Strohalm, K. Ulbrich, B. Říhová, V. Chytrý, J.B. Lloyd, R. Duncan (1991) US 5,037,883 Copolymers based on N-substituted acrylamides, N-substituted methacrylamides and N,N-disubstituted acrylamides and the method of their manufacturing. J. Kopeček, K. Ulbrich, J. Vacík, J. Strohalm, V. Chytrý, J. Drobník, J. Kálal (1977) US 4,062,831 Device for connecting or joining the ends of interrupted tubular organs in surgical operations without stitching. D. Lím, L. Šprincl, J. Kopeček (1973) US 3,774,615 Increasing permeability of reverse osmosis membranes. J. Kopeček, S. Sourirajan (1970) US 3,536,612
=== In mines === 222Rn decay products have been classified by the International Agency for Research on Cancer as being carcinogenic to humans, and as a gas that can be inhaled, lung cancer is a particular concern for people exposed to elevated levels of radon for sustained periods. During the 1940s and 1950s, when safety standards requiring expensive ventilation in mines were not widely implemented, radon exposure was linked to lung cancer among non-smoking miners of uranium and other hard rock materials in what is now the Czech Republic, and later among miners from the Southwestern US and South Australia. Despite these hazards being known in the early 1950s, this occupational hazard remained poorly managed in many mines until the 1970s. During this period, several entrepreneurs opened former uranium mines in the US to the general public and advertised alleged health benefits from breathing radon gas underground. Health benefits claimed included relief from pain, sinus problems, asthma, and arthritis, but the government banned such advertisements in 1975, and subsequent works have debated the truth of such claimed health effects, citing the documented ill effects of radiation on the body. Since that time, ventilation and other measures have been used to reduce radon levels in most affected mines that continue to operate. In recent years, the average annual exposure of uranium miners has fallen to levels similar to the concentrations inhaled in some homes.
Sources: en.wikipedia.org
=== Nathan: The Big Nasty Bully === First aired: 17 September 2009 Victims Martin and Adesh have a big problem with big bully Nathan. He's made their lives miserable and have the physical and emotional scars to prove it. Mayhem calls upon legendary MMA fighter, Andrei Arlovski to clean this bully's clock. He was knocked out and submitted five times. Nathan's taunting of Arlovski only makes his beating worse. Martin and Adesh won $10,000.
Travell preferred a 1.5-in hypodermic needle for trigger point therapy and used this needle for both injection therapy and dry needling. Travell never used an acupuncture needle. Travell had access to acupuncture needles but reasoned that they were far too thin for trigger point therapy. She preferred hypodermic needles because of their strength and tactile feedback: "A 22-gauge, 3.8-cm (1.5-in) needle is usually suitable for most superficial muscles. In hyperalgesic patients, a 25-gauge, 3.8-cm (1.5-in) needle may cause less discomfort, but will not provide the clear feeling of the structures being penetrated by the needle and is more likely to be deflected by the dense contraction knots that are the target... A 27-gauge needle, 3.8-cm (1.5-in) needle is even more flexible; the tip is more likely to be deflected by the contraction knots and it provides less tactile feedback for precision injection".
=== Supplementation === Some weight trainers also take ergogenic aids such as creatine or anabolic steroids to aid muscle growth. In a meta-analysis study that investigated the effects of creatine supplementation on repeated sprint ability, it was discovered that creatine increased body mass and mean power output. The creatine-induced increase in body mass was a result of fluid retention. The increase in mean power output was attributed to creatine's ability to counteract the lack of intramuscular phosphocreatine. Creatine does not have an effect on fatigue or maximum power output.
This resulted in the creation of the NOD-scid mice which lacked T cells, B cells, and NK cells. This mouse model permitted for a slightly higher level of human cell reconstitution. Nevertheless, a major breakthrough in this field came with the introduction of the mutant IL-2 receptor (IL2rg) gene in the NOD-scid model. This accounted for the creation of the NOD-scid-γcnull mice (NCG, NSG or NOG) models which were found to have defective signaling of interleukins IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. Researchers evolved this NSG model by knocking out the RAG1 and RAG2 genes (recombination activation genes), resulting into the RAGnull version of the NSG model that was devoid of major cells of the immune system including the natural killer cells, B lymphocytes and T lymphocytes, macrophages and dendritic cells, causing the greatest immunodeficiency in mice models so far. The limitation with this model was that it lacked the human leukocyte antigen. In accordance to this limitation, the human T cells when engrafted in the mice, failed to recognize human antigen-presenting cells, which consequated in defective immunoglobulin class switching and improper organization of the secondary lymphoid tissue. To circumvent this limitation, the next development came with the introduction of transgenes encoding for HLA I and HLA II in the NSG RAGnull model that enabled buildout of human T-lymphocyte repertoires as well as the respective immune responses. Mice with such human genes are technically human-animal hybrids.
Retinol is made industrially via total synthesis using either a method developed by BASF or a Grignard reaction utilized by Hoffman-La Roche. The two major suppliers, DSM and BASF, are believed to use total synthesis. The world market for synthetic retinol is primarily for animal feed, leaving approximately 13% for a combination of food, prescription medication, and dietary supplement use. The first industrialized synthesis of retinol was achieved by the company Hoffmann-La Roche in 1947. In the following decades, eight other companies developed their own processes. β-Ionone, synthesized from acetone, is the essential starting point for all industrial syntheses. Each process involves elongating the unsaturated carbon chain. Pure retinol is extremely sensitive to oxidization and is prepared and transported at low temperatures and oxygen-free atmospheres. When prepared as a dietary supplement or food additive, retinol is stabilized as the ester derivatives retinyl acetate or retinyl palmitate. Before 1999, three companies, Roche, BASF, and Rhone-Poulenc controlled 96% of global vitamin A sales. In 2001, the European Commission imposed total fines of 855.22 Euros on these and five other companies for their participation in eight distinct market-sharing and price-fixing cartels that dated back to 1989. Roche sold its vitamin division to DSM in 2003. DSM and BASF have the major share of industrial production.
Sources: en.wikipedia.org
== Sources == Tityus serrulatus, also known as the Brazilian yellow scorpion, is from the genus Tityus belonging to the family Buthidae. TsPep2 is identified from the venom of Tityus serrulatus by using a cDNA primer sequence based on the C-terminal amino acid sequence of KTx2 from Androctonus australis.
==== Sovereignty ==== During his tenure as prime minister, Mahathir asserted Malaysia's sovereignty over several features in the Spratly Islands, claiming Swallow Reef in 1983, Ardasier Reef and Mariveles Reef in 1986, and Investigator Shoal and Erica Reef in 1999. His administration cited Malaysia's continental shelf limits and the 1982 UNCLOS as the basis for these claims, while also responding to Vietnam's territorial activities in the region. To strengthen Malaysia's position, Mahathir oversaw the transformation of Swallow Reef into an artificial island with military fortifications, establishing it as a permanent naval outpost. Despite this militarisation, he maintained diplomatic engagement with Beijing, balancing relations with ASEAN claimants and employing a hedging strategy involving China and the United States. Mahathir's foreign policy towards China on the Spratlys was notably pragmatic. While Malaysia pursued its territorial claims, he emphasised dialogue over confrontation. In 1993, he stated that Malaysia had "no problem with China" regarding the Spratlys, and in 1994, he welcomed China's proposal for joint exploration, opposing further internationalisation of the dispute.
=== Francis Crick Medal and Lecture === The Francis Crick Medal and Lecture was established in 2003 following an endowment by his former colleague, Sydney Brenner, joint winner of the 2002 Nobel Prize in Physiology and Medicine. The lecture is delivered annually in any field of biological sciences, with preference given to the areas in which Francis Crick himself worked. Importantly, the lectureship is aimed at younger scientists, ideally under 40, or whose career progression corresponds to this age. As of 2019, Crick lectures have been delivered by Julie Ahringer, Dario Alessi, Ewan Birney, Simon Boulton, Jason Chin, Simon Fisher, Matthew Hurles, Gilean McVean, Duncan Odom, Geraint Rees, Sarah Teichmann, M. Madan Babu and Daniel Wolpert.
The LLNL chemistry, materials, and life science research focuses on chemical engineering, nuclear chemistry, materials science, and biology and bio-nanotechnology. Physics thrust areas include condensed matter and high-pressure physics, optical science and high energy density physics, medical physics and biophysics, and nuclear, particle and accelerator physics. In the area of energy and environmental science, Livermore's emphasis is on carbon and climate, energy, water and the environment, and the national nuclear waste repository. The LLNL engineering activities include micro- and nanotechnology, lasers and optics, biotechnology, precision engineering, nondestructive characterization, modeling and simulation, systems and decision science, and sensors, imaging and communications. LLNL is a computing organization with capabilities in computer science, software engineering, data science, modeling and simulation, information technology, and cyber security. Lawrence Livermore National Laboratory has worked out several energy technologies in the field of coal gasification, shale oil extraction, geothermal energy, advanced battery research, solar energy, and fusion energy. Main oil shale processing technologies worked out by the Lawrence Livermore National Laboratory are LLNL HRS (hot-recycled-solid), LLNL RISE (in situ extraction technology) and LLNL radiofrequency technologies.
In the laboratory it is a common precipitant and cryoprotectant in protein crystallography. Since hexylene glycol is compatible with polar and nonpolar molecules, it competes with the solvent in a crystallography experiment causing the protein to precipitate. Hexylene glycol is so effective in protein crystallography because its amphiphilic nature and small, flexible structure allows it to bind to many different locations on a protein secondary structure including alpha helices and beta sheets. When hexylene glycol binds to these different locations, water is removed and the protein crystals anneal, which prevents ice formation during cryocrystallography techniques. Incorporation of hexylene glycol into solution has been known to improve the resolution of X-ray diffraction making protein structures easily identifiable. Additionally hexylene glycol is not a strong denaturing agent and thus does not significantly alter the structure of a protein during the crystallography procedure. Hexylene glycol is also used as a lubricant for polishing specimens in metallography. Like related diols, it forms borate esters.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.